slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 11,551-11,580
Pages 3,225
Rows per page 30
Component
11,551-11,580 of 96,741
106
The slide uses a red box to highlight the 'n=17' discrepancy in the source text.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
107
The slide uses an FDA review document to highlight a safety risk (QTc prolongation) that the company allegedly downplays.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
108
The slide uses a direct quote from a study to argue that 'malaise sensation' is a euphemism for 'fainting' (syncope) to downplay cardiotoxicity.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
123
The slide uses a red box to highlight a specific data point (40mg dose) in a table to support the argument of inconsistent reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
125
The slide uses a specific data table to support a broader narrative of corporate non-transparency regarding PK data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
131
The slide uses a quote from a pharmacology consultant to argue that safety margins are overestimated due to drug accumulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
132
The slide highlights a specific discrepancy in an FDA review document (page 32) where the graph title claims 'steady state Cmax' but the underlying data is from a single dose.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
135
The slide uses a 'before-after' logic to expose a flaw in regulatory reliance on single-dose data. The red box highlights the critical 'Upper limit TQT' values in the corrected table.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
138
The slide uses direct excerpts from the drug's prescribing information to build a case against its safety profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
140
The slide uses a quote from a consultant to challenge the validity of the company's (Harmony) data submitted to the FDA.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
149
The slide uses regulatory documents (EMA/FDA) and primary research (prescriber interviews) to build a case for potential safety risks.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
156
The slide uses a combination of narrative analysis and a specific case study excerpt to challenge the safety profile of pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
175
The slide uses a list of adverse events to build a case for cardiotoxicity, highlighting specific fatal and serious outcomes.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
211
The slide uses a table from a Lancet paper to argue that pitolisant's performance was inferior to modafinil, contradicting the company's narrative.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
212
The slide uses a pie chart to highlight that 38% of study participants were in Russia, suggesting a lack of geographic diversity and potential data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
214
The slide uses excerpts from French regulatory documents to prove the existence and negative results of the unpublished HARMONY 4 trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
217
The slide uses a screenshot of the ESS website to undermine the credibility of the clinical trial endpoint.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
222
The slide uses FDA biometrics review data to challenge the efficacy timeline of the drug Wakix (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
223
The author argues that the discrepancy hides a trend reversal that would undermine the trial's efficacy claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
228
The slide highlights a recurring methodological inconsistency across multiple clinical trials, suggesting regulatory oversight failure.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
229
The slide highlights a specific regulatory failure/contradiction regarding the acceptance of post-hoc analysis in clinical trials.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
230
The slide uses a redacted document image to illustrate the lack of transparency in the FDA's review process compared to the EMA's.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
234
The slide details three specific statistical and methodological reasons for the FDA's rejection of the HARMONY 1 study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
237
The slide uses a 'villain' framing to discredit the reliability of clinical data originating from Russia and Eastern Europe.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
238
The slide highlights a discrepancy between the trial paper's log-scale chart and the actual linear-scale data, suggesting data manipulation or misleading presentation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
239
The slide highlights the ambiguity in the definition of 'cataplexy' used in the study protocol, leading to potential data reliability issues.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
241
The slide uses red text for emphasis on specific criticisms (dose response, centre effect).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
259
The slide highlights a negative expert opinion on drug efficacy, contrasting it with the prescriber's own behavior.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
289
The slide uses a Wikipedia table to explain DEA drug schedules to frame the competitive landscape.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
298
The slide uses a 'fraud-exposure' approach by highlighting circular citations and methodological weaknesses in the foundational research.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits